MedTrace Logo

TAP vs QLB in Patients After Cesarean Delivery

NCT03404908 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2023-11-24

No results posted yet for this study

Summary

Comparison of two types of analgesia after cesarean section All patients will be anesthetized with spinal technique. Ultrasound-guided transversus abdominis plane or quadratus lumborum block to treat postoperative pain. Postoperative pain will be measured with visual-analog scale (VAS). 1, 2, 6 months after surgery each patient will be called to assess neuropathic pain with Neuropathic Pain Symptom Inventory (NPSI).

Conditions

  • Cesarean Section
  • Postoperative Pain

Interventions

PROCEDURE

TAP (transversus abdominis plane block)

the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).

PROCEDURE

QL (quadratus lumborum block)

the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).

DRUG

Ropivacaine

In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)

DEVICE

Needle

Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study

DRUG

paracetamol

Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day

DRUG

metamizole

Intravenous metamizole will be used (1.0 gram), up to 4 grams per day

DRUG

Ketoprofen

Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day

DRUG

Morphine

Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)

Sponsors & Collaborators

  • Medical University of Lublin

    lead OTHER

Principal Investigators

  • Mirosław Czuczwar, M.D., PhD · Medical University of Lublin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-07
Primary Completion
2019-01-14
Completion
2019-04-17

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03404908 on ClinicalTrials.gov